Abstract Background: The newer generation of Bioresorbable Vascular Scaffold ABSORB (BVS
1.1) showed better outcome in regard to scaffold area reduction as a result of improved scaffold
design and enhanced polymer processing.
Objective: To assess the safety and efficacy of treating significant native coronary artery stenosis
using ABSORB BVS.
Methods: Ninety-nine patients with de novo native significant coronary artery stenosis were selected
between September 2012 and September 2014 and were treated using ABSORB BVS. For each
patient, the target and the peri-scaffold segments (5 mm proximal and distal to the scaffold edge)
were analyzed by Quantitative Coronary Angiography (QCA) and Intravascular Ultrasound (IVUS)
immediately after the procedure and at one year of follow-up. The major clinical endpoint was
ischemia-driven major adverse cardiac events (ID-MACE) defined as a composite of cardiac death,
myocardial infarction or ischemia-driven target lesion revascularization (ID-TLR).
Results: At one year, the overall scaffold area did not demonstrate any significant change. The
angiographic insegment late lumen loss was estimated to be 0.11 ± 0.19 mm, while the IVUS assessment
revealed a non-significant decrease in the minimal lumen area by 0.5% (p= 0.79), without significant
change in the mean lumen area. There were no reported cardiac deaths. However, two cases
of ID-TLR were recorded, one case with STEMI after two weeks due to thrombosis at the distal edge
of the BVS and another case with restenosis after one year. Both were treated with metallic drug-eluting stents (Xience V). At one year the overall ID-MACE was found to be 2%.
Conclusion: The performance of ABSORB BVS in the treatment of significant de novo native coronary
artery stenosis makes it an attractive option with favorable early and late outcome. |
